DOCSLIB.ORG

Copyrighted Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff tumour 137.52 malignant 87.3, 87.5, 147.14–15 plaque 35.26, 35.28 clinical features 90.61–3 abscesses 3.38 management 87.5 squamous cell carcinoma secondary complications/co-morbidities 90.63 anal 113.24, 113.25–6 oral lesions 110.10 prevention 142.32 definition 90.59 aseptic abscess syndrome 49.17 paraneoplastic 87.5, 147.15–16, 152.1 subcorneal pustular dermatosis differential diagnosis 90.62–3 breast 116.24 pathophysiology 87.3–4 49.15 disease course 90.63 filler adverse reaction 157.9 predisposing factors 87.4 Vohwinkel syndrome treatment 65.57 epidemiology 90.59–60 glanders 26.53, 26.54 prognosis 87.5 Ackerman tumour see verrucous investigations 90.63 hidradenitis suppurativa 92.4, 92.5 unilateral 87.5 carcinoma management 90.63–4 differential diagnosis 92.7 variants 87.4–5 acne pathophysiology 90.60–1 HIV infection 31.20 vulval 112.21 agminate 90.28 prognosis 90.63 immunodeficiency association 148.15 acanthosis palmaris 147.15–16 antibiotic therapy 19.43 scarring 90.63 intraoral 110.58 Acari 34.35, 34.36, 34.37–9 ocular side effects 109.46 severity 90.63 krokodil abuse 121.3 Acaridae 34.48 arthritis association 154.10 variants 90.62 subungual 95.37–8 accelerated rheumatoid nodulosis 99.15 comedonal 90.1, 90.2–3, 90.21 Propionibacterium acnes 26.43 acantholysis 3.33–4, 66.1, 66.2, 66.4 acetone 95.63 management 90.38, 90.39–40 psychological impact 11.4 pemphigus 50.3 acetyl hexapeptide 3 156.5 mid-facial 90.62 pyogenic sterile arthritis, pyoderma acantholytic dermatoses acetylcholine 2.8, 8.52 treatment algorithm 90.38 gangrenosum and acne Hailey–Hailey disease variants 66.12 atopic eczema 41.15 cosmetica 90.17 syndrome 45.3, 45.8 see also transient acantholytic dermatosis itching in skin disease 83.6 defensin activity 8.14 quality of life measurement 16.6 acantholytic disorders, inherited 66.1–13 acetylcholine receptor antibodies 50.3 detergent 90.17 surgery 20.47 see also Darier disease; Hailey–Hailey Achenbach syndrome 101.6, 123.13 ectopic 92.1 acne aestivalis 93.6 disease achondroplasia, osteogenesis imperfecta endocrine disorder skin signs 149.10 acne conglobata 90.50–1, 90.54–6, 92.2, acantholytic dyskeratosis 71.24 differential diagnosis 72.10 environmental, differential 154.10 focal 110.19 aciclovir 19.44 diagnosis 90.57 acne fulminans differential acanthoma fissuratum 123.13–14 erythema multiforme 47.6 environmental pollution 90.56–7 diagnosis 90.52, 90.56 acanthosis 3.34 herpes simplex virus excoriée 90.23 assessment 90.56 Bowen disease 142.17 inCOPYRIGHTED HIV 31.23 MATERIALgranulomatous 90.24 associated diseases 90.54 peristomal papules 114.111 neonatal 116.22 hidradenitis suppurativa 92.2 clinical features 90.55–6 acanthosis nigricans 64.3, 87.2–5, 147.14–15 post-herpetic neuralgia 84.4–5 hirsutism association 89.65 complications 90.56 acquired generalized resistance 31.23 hyperandrogenism 145.18 definition 90.54 lipodystrophy 100.3 topical 18.13 infantile 90.59, 90.61–2, 90.63, 117.5 differential diagnosis 90.55 acral 87.4–5 varicella-zoster virus 25.30, 31.23 differential diagnosis 90.62 dissecting cellulitis of scalp associated disorders 87.3 acid glycosaminoglycans 59.1 inversa 92.1 association 107.8 benign 147.14 acid lipase 65.10 isotretinoin treatment 11.4 epidemiology 90.54 clinical features 87.4–5 acid orcein–Giemsa stain 3.8, 3.9 joint symptom association 154.10 genetics 90.54 confluent and reticulated papillomatosis acid phosphatase 2.43, 8.41 keloid-like 96.46, 96.47 hidradenitis suppurativa differential differential diagnosis 87.7 lysosomal 8.44 mechanical 90.24 diagnosis 113.21 congenital generalized lipodystrophies acids, chemical burns 129.12 mid-childhood 90.59, 90.60, 90.62 infants 90.62 74.1 Acinetobacter 26.50 differential diagnosis 90.63 management 90.56, 90.57 Darier disease differential Acinetobacter baumannii 34.18 necrotica 90.32 pathophysiology 90.54 diagnosis 66.4 acitretin 19.37, 31.16 neonatal 90.59, 90.61, 90.63 acné excoriée 86.15–16, 90.23 Rook’s Textbook of Dermatology, Ninth Edition. Edited by Christopher Griffiths, Jonathan Barker, Tanya Bleiker, Robert Chalmers and Daniel Creamer. © 2016 John Wiley & Sons, Ltd. Published 2016 by John Wiley & Sons, Ltd. Companion website: www.rooksdermatology.com bindex_4blank.indd 1 6 January 2016 3:29 PM 2 Index acne fulminans 90.50–3, 154.10 systemic therapy 90.41–4 acral peeling skin syndrome (APSS) 65.27, actin 3.21 acne conglobata differential topical therapy 90.40–1 71.6, 71.7 actinic cheilitis 110.78–9 diagnosis 90.52, 90.56 papulopustular rosacea differential keratolysis exfoliativa differential carbon dioxide laser ablation 23.18 assessment 90.52–3 diagnosis 91.10 diagnosis 87.24 photodynamic therapy 22.5 associated disorders 90.50–1 pathophysiology 90.18–20 acral persistent papular mucinosis 59.6, actinic comedonal plaque 96.3 clinical features 90.51–2 periorificial dermatitis differential 59.7 actinic dermatitis see chronic actinic complications 90.53 diagnosis 91.18 acral self-healing collodion baby 116.19 dermatitis definition 90.50 photoaggravated, actinic folliculitis acroangiodermatitis 101.5 actinic elastosis see solar elastosis differential diagnosis 90.52 differential diagnosis 93.6 Kaposi sarcoma, differential actinic folliculitis 93.6 disease course 90.53 predisposing factors 90.12–13, 90.14–16, diagnosis 139.4 actinic granuloma 96.25–7 epidemiology 90.50–1 90.16–18 acrocyanosis 81.10, 125.5–6 solar elastosis association 96.3 genetics 90.51 pregnancy 90.17, 115.8–9 neonates 116.3 actinic keratoses 142.1–7, 142.8, 142.9–11 infections 90.51 prognosis 90.36 proximal nail fold capillaroscopy 95.52 basal cell carcinoma association 125.13, investigations 90.52–3 Pseudomonas aeruginosa infection 26.52 Raynaud phenomenon differential 141.2 isotretinoin-induced flare 90.51 psychological problem association 90.23 diagnosis 125.9 benign lichenoid keratosis differential management 90.53 psychosocial effects 90.34–5 Sneddon syndrome 101.21 diagnosis 133.7 pathophysiology 90.51 pyogenic granuloma 90.36 acrodermatitis chronica atrophicans 96.13– Bowen disease differential prognosis 90.53 quality of life impact 90.33, 90.34, 90.34 14, 96.19 diagnosis 142.19 variants 90.52 rosacea conglobata differential Lyme disease 140.38 bowenoid 142.3 acne inversa see hidradenitis suppurativa diagnosis 91.16 sclerosing panniculitis differential causative organisms 142.3 acne keloidalis scarring 90.22, 90.23, 90.24, 90.35 diagnosis 99.29 chondrodermatitis nodularis differential nuchae 93.3–4, 123.16 mimics 90.32 acrodermatitis chronica migrans 26.70 diagnosis 108.9 scarring 90.32 seborrhoea 90.36 acrodermatitis continua of clinical features 142.3–6 acne mechanica 123.15, 123.16 severe Hallopeau 35.40–2 immunocompromised acne of chemical origin treatment 90.44–8 clinical features 35.41–2 patients 146.10–11 clinical features 130.11–12 treatment algorithm 90.39 definition 35.40 complications/co-morbidity 142.6 differential diagnosis 130.11 severity rating 90.32–3, 90.36, 90.37 differential diagnosis 35.42 cutaneous horn differential hidradenitis suppurativa differential sinus tracts 90.22, 90.23 epidemiology 35.41 diagnosis 142.12 diagnosis 113.21 sleep deprivation 90.16–17 investigations 35.42 definition 142.1 management 130.12 smoking 90.16 management 35.42 differential diagnosis 142.4–5 occupational disorders 130.10–12 stress factors 90.16–17 pathophysiology 35.41 disease course 142.6 Acne Quality of Life Scale (AQOL) 16.6 suicide risk 90.34–5 psoriasis 95.41 disseminated superficial actinic Acne Symptom and Impact Scale tuberous sclerosis complex differential radiotherapy 24.6 porokeratosis differential (ASIS) 16.6 diagnosis 80.12 acrodermatitis dysmetabolica 63.26, 71.24 diagnosis 142.16 acne vulgaris 90.1–3, 90.3–4, 90.5–6, 90.7, UV radiation 90.17 acrodermatitis enteropathica 63.26, epidemiology 142.2 90.8–13, 90.14–16, 90.16–50 variants 90.22–4 81.17–18 eyelid 109.46 acneform drug eruption differential acneform eruptions 120.3 breastfed infants 63.25–6 Flegel disease differential diagnosis 118.17
Recommended publications
  • Chloracne: from Clinic to Research

    Chloracne: from Clinic to Research

    DERMATOLOGICA SINICA 30 (2012) 2e6 Contents lists available at SciVerse ScienceDirect Dermatologica Sinica journal homepage: http://www.derm-sinica.com REVIEW ARTICLE Chloracne: From clinic to research Qiang Ju 1, Kuochia Yang 2, Christos C. Zouboulis 3, Johannes Ring 4, Wenchieh Chen 4,* 1 Department of Dermatology, Shanghai Skin Disease and STD Hospital, Shanghai, People’s Republic of China 2 Department of Dermatology, Changhua Christian Hospital, Changhua, Taiwan 3 Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany 4 Department of Dermatology and Allergy, Technische Universität München, Munich, Germany article info abstract Article history: Chloracne is the most sensitive and specific marker for a possible dioxin (2,3,7,8-tetrachlorodibenzo-p- Received: Oct 31, 2011 dioxin) intoxication. It is clinically characterized by multiple acneiform comedone-like cystic eruptions Revised: Nov 9, 2011 mainly involving face in the malar, temporal, mandibular, auricular/retroauricular regions, and the Accepted: Nov 9, 2011 genitalia, often occurring in age groups not typical for acne vulgaris. Histopathology is essential for adefinite diagnosis, which exhibits atrophy or absence of sebaceous glands as well as infundibular Keywords: dilatation or cystic formation of hair follicles, hyperplasia of epidermis, and hyperpigmentation of aryl hydrocarbon receptor stratum corneum. The appearance of chloracne and its clinical severity does not correlate with the blood chloracne “ ” 2,3,7,8-tetrachlorodibenzo-p-dioxin levels of dioxins. Pathogenesis of chloracne remains largely unclear. An aryl hydrocarbon receptor - polyhalogenated aromatic hydrocarbons mediated signaling pathway affecting the multipotent stem cells in the pilosebaceous units is probably sebaceous gland the major molecular mechanism inducing chloracne.
  • Differences in Genotype, Clinical Features, and Inflammatory

    Differences in Genotype, Clinical Features, and Inflammatory

    RESEARCH Differences in Genotype, Clinical Features, and Inflammatory Potential of Borrelia burgdorferi sensu stricto Strains from Europe and the United States Tjasa Cerar,1 Franc Strle,1 Dasa Stupica, Eva Ruzic-Sabljic, Gail McHugh, Allen C. Steere, Klemen Strle Borrelia burgdorferi sensu stricto isolates from patients with B. afzelii, which usually remains localized to the skin, with erythema migrans in Europe and the United States and B. garinii, which is usually associated with nervous were compared by genotype, clinical features of infection, system involvement (1). B. burgdorferi infection is rare in and inflammatory potential. Analysis of outer surface pro- Europe; little is known about its clinical course there. In tein C and multilocus sequence typing showed that strains the United States, B. burgdorferi is the sole agent of Lyme from these 2 regions represent distinct genotypes. Clinical borreliosis; in the northeastern United States, it is particu- features of infection with B. burgdorferi in Slovenia were similar to infection with B. afzelii or B. garinii, the other 2 larly arthritogenic (1,2). For all 3 species, the first sign of Borrelia spp. that cause disease in Europe, whereas B. infection is often an erythema migrans lesion. However, B. burgdorferi strains from the United States were associ- burgdorferi infection in the United States is associated with ated with more severe disease. Moreover, B. burgdorferi a greater number of disease-associated symptoms and more strains from the United States induced peripheral blood frequent hematogenous dissemination than B. afzelii or B. mononuclear cells to secrete higher levels of cytokines garinii infection in Europe (4–7).
  • ID 2 | Issue No: 4.1 | Issue Date: 29.10.14 | Page: 1 of 24 © Crown Copyright 2014 Identification of Corynebacterium Species

    ID 2 | Issue No: 4.1 | Issue Date: 29.10.14 | Page: 1 of 24 © Crown Copyright 2014 Identification of Corynebacterium Species

    UK Standards for Microbiology Investigations Identification of Corynebacterium species Issued by the Standards Unit, Microbiology Services, PHE Bacteriology – Identification | ID 2 | Issue no: 4.1 | Issue date: 29.10.14 | Page: 1 of 24 © Crown copyright 2014 Identification of Corynebacterium species Acknowledgments UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website https://www.gov.uk/uk- standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical- laboratories. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see https://www.gov.uk/government/groups/standards-for-microbiology-investigations- steering-committee). The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content. For further information please contact us at: Standards Unit Microbiology Services Public Health England 61 Colindale Avenue London NW9 5EQ E-mail: [email protected] Website: https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality- and-consistency-in-clinical-laboratories UK Standards for Microbiology Investigations are produced in association with: Logos correct at time of publishing. Bacteriology – Identification | ID 2 | Issue no: 4.1 | Issue date: 29.10.14 | Page: 2 of 24 UK Standards for Microbiology Investigations | Issued by the Standards Unit, Public Health England Identification of Corynebacterium species Contents ACKNOWLEDGMENTS .........................................................................................................
  • Compensation for Occupational Skin Diseases

    Compensation for Occupational Skin Diseases

    ORIGINAL ARTICLE http://dx.doi.org/10.3346/jkms.2014.29.S.S52 • J Korean Med Sci 2014; 29: S52-58 Compensation for Occupational Skin Diseases Han-Soo Song1 and Hyun-chul Ryou2 The Korean list of occupational skin diseases was amended in July 2013. The past list was constructed according to the causative agent and the target organ, and the items of that 1 Department of Occupational and Environmental list had not been reviewed for a long period. The revised list was reconstructed to include Medicine, College of Medicine, Chosun University, Gwangju; 2Teo Center of Occupational and diseases classified by the International Classification of Diseases (10th version). Therefore, Environmental Medicine, Changwon, Korea the items of compensable occupational skin diseases in the amended list in Korea comprise contact dermatitis; chemical burns; Stevens-Johnson syndrome; tar-related skin diseases; Received: 19 December 2013 infectious skin diseases; skin injury-induced cellulitis; and skin conditions resulting from Accepted: 2 May 2014 physical factors such as heat, cold, sun exposure, and ionized radiation. This list will be Address for Correspondence: more practical and convenient for physicians and workers because it follows a disease- Han-Soo Song, MD based approach. The revised list is in accordance with the International Labor Organization Department of Occupational and Environmental Medicine, Chosun University Hospital, 365 Pilmun-daero, Dong-gu, list and is refined according to Korean worker’s compensation and the actual occurrence of Gwangju 501-717, Korea occupational skin diseases. However, this revised list does not perfectly reflect the actual Tel: +82.62-220-3689, Fax: +82.62-443-5035 E-mail: [email protected] status of skin diseases because of the few cases of occupational skin diseases, incomplete statistics of skin diseases, and insufficient scientific evidence.
  • Symmetrical Intertriginous and Flexural Exanthema Due to Bortezomib (A Proteasome Inhibitor) Given for Myeloma

    Symmetrical Intertriginous and Flexural Exanthema Due to Bortezomib (A Proteasome Inhibitor) Given for Myeloma

    Acta Derm Venereol 2016; 96: 995–996 SHORT COMMUNICATION Symmetrical Intertriginous and Flexural Exanthema due to Bortezomib (a Proteasome Inhibitor) Given for Myeloma Nausicaa Malissen1, Jean-Luc Bourrain1, Anca Chiriac2, Aline Montet1, Laure Vincent3, Olivier Dereure1 and Aurélie Du-Thanh1* 1Dermatology Department, 2Pneumology – Allergology Department, Montpellier University Hospital, and 3Clinical Hematology Department, Montpellier University Hospital, 80 avenue Augustin Fliche, FR-34295 Montpellier cedex 5, France. *E-mail: [email protected] Accepted Mar 17, 2016; Epub ahead of print Mar 22, 2016 Bortezomib is a selective proteasome inhibitor currently discovered, high-risk smouldering multiple myeloma. used as standard of care in the treatment of multiple my- He disclosed no other relevant medical background and eloma. Cutaneous side-effects are frequent, as reported in did not receive any other medication, except for the a phase 3 randomized study (1), in which 57% and 70% following regimen, implemented 15 days before occur- of patients experienced a grade 3 or higher skin toxicity rence of the skin eruption and combining subcutaneous with subcutaneous and intravenous administration, re- bortezomib, 1 mg/m2, on days 1, 4, 8 and 11, thalido- spectively. However, these adverse effects are usually mide, 100 mg daily, dexamethasone, 40 mg daily from poorly described in haematological-based reports, and day 1 to day 4, sulfamethoxazole trimethoprim (SMX- range from benign skin eruption to lethal epidermal TMP) and valaciclovir as prophylactic measures. Initial necrolysis (2), thus it is important to provide a more clinical survey revealed a pruritic and symmetrically specific description when they occur. distributed intertriginous, maculopapular exanthema, localized to the axillae, antecubital fossae, groin, neck and buttocks (Fig.
  • Disfiguring Ulcerative Neutrophilic Dermatosis Secondary To

    Disfiguring Ulcerative Neutrophilic Dermatosis Secondary To

    RESIDENT HIGHLIGHTS IN COLLABORATION WITH COSMETIC SURGERY FORUM Disfiguring Ulcerative Neutrophilic Dermatosis Secondary to Doxycycline and Isotretinoin in an Bahman Sotoodian, MD Top 10 Fellow and Resident Adolescent Boy With Grant Winner at the 8th Cosmetic Surgery Forum Acne Conglobata Bahman Sotoodian, MD; Paul Kuzel, MD, FRCPC; Alain Brassard, MD, FRCPC; Loretta Fiorillo, MD, FRCPC copy accompanied by systemic symptoms including fever and leuko- RESIDENT cytosis. We report a challenging case of a 13-year-old adolescent PEARL boy who acutely developed hundreds of ulcerative plaques as well • Doxycycline and isotretinoin have been widely used as systemicnot symptoms after being treated with doxycycline and for treatment of inflammatory and nodulocystic acne. isotretinoin for acne conglobata. He was treated with prednisone, Although outstanding results can be achieved, para- dapsone, and colchicine and had to switch to cyclosporine to doxical worsening of acne while starting these medi- achieve relief from his condition. cations has been described. In patients with severeDo Cutis. 2017;100:E23-E26. acne (ie, acne conglobata), initiation of doxycycline and especially isotretinoin at regular dosages as the sole treatment can impose devastating risks on the patient. These patients are best treated with a combi- cne fulminans is an uncommon and debilitating nation of low-dose isotretinoin (at the beginning) with disease that presents as an acute eruption of nodular a moderate dose of steroids, which should be gradu- A and ulcerative acne lesions with associated systemic ally tapered while the isotretinoin dose is increased to symptoms.1,2 Although its underlying pathophysiology is 0.5 to 1 mg/kg once daily.
  • Pathological Investigation of Rosacea with Particular Regard Of

    Pathological Investigation of Rosacea with Particular Regard Of

    CORE Metadata, citation and similar papers at core.ac.uk Provided by White Rose E-theses Online A Clinico-Pathological Investigation of Rosacea with Particular Regard to Systemic Diseases Dr. Mustafa Hassan Marai Submitted in accordance with the requirements for the degree of Doctor of Medicine The University of Leeds School of Medicine May 2015 “I can confirm that the work submitted is my own and that appropriate credit has been given where reference has been made to the work of others” “This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement” May 2015 The University of Leeds Dr. Mustafa Hassan Marai “The right of Dr Mustafa Hassan Marai to be identified as Author of this work has been asserted by him in accordance with the Copyright, Designs and Patents Act 1988” Acknowledgement Firstly, I would like to thank all the patients who participate in my rosacea study, giving their time and providing me with all of the important information about their disease. This is helped me to collect all of my study data which resulted in my important outcome of my study. Secondly, I would like to thank my supervisor Dr Mark Goodfield, consultant Dermatologist, for his continuous support and help through out my research study. His flexibility, understanding and his quick response to my enquiries always helped me to relive my stress and give me more strength to solve the difficulties during my research. Also, I would like to thank Dr Elizabeth Hensor, Data Analyst at Leeds Institute of Molecular Medicine, Section of Musculoskeletal Medicine, University of Leeds for her understanding the purpose of my study and her help in analysing my study data.
  • Impact of Photostability and UVA/UVA-Blue Light Protection On

    Impact of Photostability and UVA/UVA-Blue Light Protection On

    Thannhausen, Germany, August 06, 2019 Thannhausen, Germany, | Volume 145 Volume | 7+8/19 powered by skin whitening Natural Extremolyte Fights Pigmentation Caused by Environmental Stressors 7/8 Impact of Photostability 2019 english solubilizers Effective Natural Alternatives to Synthetic Solubilizers – a Comparison Study sun care and UVA/UVA-Blue Light Impact of Photostability and UVA/UVA-Blue Light Protection on Free Radical Generation Blue Light Induced Hyperpigmentation in Skin and How to Prevent it Photostabilisation: The Key to Robust, Protection on Free Radical Safe and Elegant Sunscreens disinfection Skin and Environmentally Safe and Universally Useable Disinfectant for all Generation Surfaces with Green Technology skin/hair care Natural Oil Metathesis Unveils High-Performance Weightless Cosmetic Emollients M. Sohn, S. Krus, K. Jung, M. Seifert, M. Schnyder SOFW Journal 7+8/19 | Volume 145 | Thannhausen, Germany, August 06, 2019 personal care | sun care Impact of Photostability and UVA/UVA-Blue Light Protection on Free Radical Generation M. Sohn, S. Krus, K. Jung, M. Seifert, M. Schnyder abstract he impact of UV-filter combination on the number of free radicals generated in sunscreen formulations and the skin follow- Ting UV-VIS irradiation was assessed via electron spin resonance spectroscopy using a spin-probing approach. Four UV-filter combinations that differed in their photostability and range of UVA absorbance coverage were investigated. Fewer free radicals were generated in the sunscreen formulation when a photostable UVA filter system was used, compared to a stabilized UVA fil- ter system. Additionally, fewer free radicals were generated in the skin when a sunscreen with long UVA protection extending to the short visible range was used, compared to a sunscreen with minimal UVA protection.
  • Pathogenesis of Rosacea Anetta E

    Pathogenesis of Rosacea Anetta E

    REVIEW Pathogenesis of Rosacea Anetta E. Reszko, MD, PhD; Richard D. Granstein, MD Rosacea is a chronic, common skin disorder whose pathogenesis is incompletely understood. An inter- play of multiple factors, including genetic predisposition and environmental, neurogenic, and microbial factors, may be involved in the disease process. Rosacea subtypes, identified in the recently published standard classification system by the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea, may in fact represent different disease processes, and identifying subtypes may allow investigators to pursue more precisely focused studies. New developments in molecular biology and genetics hold promise for elucidating the interplay of the multiple factors involved in the pathogen- esis of rosacea, as well as providing the bases for potential new therapies. osacea is a common, chronic skin disorder and secondary features needed for the clinical diagnosis primarily affecting the central and con- of rosacea. Primary features include flushing (transient vex areas of COSthe face. The nose, cheeks, DERM erythema), persistent erythema, papules and pustules, chin, forehead, and glabella are the most and telangiectasias. Secondary features include burn- frequently affected sites. Less commonly ing and stinging, skin dryness, plaque formation, dry affectedR sites include the infraorbital, submental, and ret- appearance, edema, ocular symptoms, extrafacial mani- roauricular areas, the V-shaped area of the chest, and the festations, and phymatous changes. One or more of the neck, the back, and theDo scalp. Notprimary Copy features is needed for diagnosis.1 The disease has a variety of clinical manifestations, Several authors have theorized that rosacea progresses including flushing, persistent erythema, telangiecta- from one stage to another.2-4 However, recent data, sias, papules, pustules, and tissue and sebaceous gland including data on therapeutic modalities of various sub- hyperplasia.
  • Evaluation of Symptom Heterogeneity in Neuropathic Pain Using Assessments of Sensory Functions

    Evaluation of Symptom Heterogeneity in Neuropathic Pain Using Assessments of Sensory Functions

    Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics Evaluation of Symptom Heterogeneity in Neuropathic Pain Using Assessments of Sensory Functions Kathrin Arning and Ralf Baron Division of Neurological Pain Research and Therapy, Department of Neurology, Christian-Albrechts-Universität Kiel, Germany Summary: Classification of neuropathic pain has been based can be elucidated in each patient. Moreover, in questionnaires on disease entities, anatomical localization, or histological ob- the verbal descriptors can depict the quality and intensity of the servations. Over the past decade, there has been an explosion in individual pain. The approach of classifying and subgrouping our understanding of the basic mechanisms of neuropathic pain. patients with neuropathic pain on the basis of symptoms or The exciting advances in basic science are paralleled by the signs opens up new possibilities for stratifying patients in clin- recognition from clinical investigations that neuropathic pain is ical trials. First, in clinical proof-of-concept trials the study not a monolithic entity, but instead presents as a composite of population can be enriched prospectively on the basis of entry pain and other sensory symptoms. Attempts are under way to criteria defined a priori. This enrichment with patients who supplement the traditional classification with a classification potentially require a specific treatment should increase the like- that links pain and sensory symptoms with neurobiological lihood for positive trial outcomes. Second, in clinical practice it mechanisms. This mechanism- or symptom-based classifica- becomes possible to establish an individualized therapy—that tion takes both negative and positive sensory symptoms into is, to identify the particular patients who require a specific account.
  • Symmetrical Drug-Related Intertriginous and Flexural Exanthema Secondary to Topical 5-Fluorouracil

    Symmetrical Drug-Related Intertriginous and Flexural Exanthema Secondary to Topical 5-Fluorouracil

    Symmetrical Drug-Related Intertriginous and Flexural Exanthema Secondary to Topical 5-Fluorouracil Roxann Powers, MD; Rachel Gordon, MD; Kenrick Roberts, MD; Rodney Kovach, MD We report the case of a 56-year-old man who fossae and axillae. His dermatologist stopped the developed a distinctive skin eruption after treat- 5-FU and started prednisone, erythromycin, hydro- ing actinic keratoses on the dorsal aspects of cortisone ointment, and fexofenadine hydrochloride. his right and left hands with topical 5-fluorouracil Over the next week, the areas became eroded and the (5-FU). The distribution of his rash was charac- pain worsened. A biopsy was performed. The hydro- teristic of symmetrical drug-related intertriginous cortisone was discontinued and he was referred for a and flexural exanthema (SDRIFE), also known as second opinion. baboon syndrome. Medications at presentation included erythromycin, Cutis. 2012;89:225-228. fexofenadine hydrochloride, acetaminophen-codeine, CUTISprednisone, petrolatum ointment, metformin Case Report hydrochloride, enalapril maleate, ranitidine hydro- A 56-year-old man with a history of diabetes mel- chloride, simvastatin, triamterene/hydrochlorothiazide, litus, hypertension, hyperlipidemia, reflux, squamous aspirin, and omeprazole. He reported no cell carcinoma in situ of his right hand, and actinic known allergies. keratoses of the right Doand left hands presentedNot with a PhysicalCopy examination revealed an overweight painful, burning, pruritic, erythematous, and blister- man who appeared agitated and reported substantial ing rash on his medial thighs, scrotum, penis, antecu- discomfort. He had well-demarcated, violaceous, red bital fossae, axillae, and dorsal hands. The patient had erosions on his medial thighs (Figure 1), scrotum, a successful history of treatment of actinic keratosis and penis; erythematous denuded patches in the on his right hand with topical 5-fluorouracil (5-FU) antecubital fossae (Figure 2) and axillae; and crusty 8 years prior to presentation.
  • Nail Involvement in Alopecia Areata

    Nail Involvement in Alopecia Areata

    212 CLINICAL REPORT Nail Involvement in Alopecia Areata: A Questionnaire-based Survey on DV Clinical Signs, Impact on Quality of Life and Review of the Literature 1 2 2 1 cta Yvonne B. M. ROEST , Henriët VAN MIDDENDORP , Andrea W. M. EVERS , Peter C. M. VAN DE KERKHOF and Marcel C. PASCH1 1 2 A Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, and Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, The Netherlands Alopecia areata (AA) is an immune-mediated disease at any age, but as many as 60% of patients with AA will causing temporary or permanent hair loss. Up to 46% present with their first patch before 20 years of age (4), and of patients with AA also have nail involvement. The prevalence peaks between the 2nd and 4th decades of life (1). aim of this study was to determine the presence, ty- AA is a lymphocyte cell-mediated inflammatory form pes, and clinical implications of nail changes in pa- of hair loss in which a complex interplay between genetic enereologica tients with AA. This questionnaire-based survey eva- factors and underlying autoimmune aetiopathogenesis V luated 256 patients with AA. General demographic is suggested, although the exact aetiological pathway is variables, specific nail changes, nail-related quality of unknown (5). Some studies have shown association with life (QoL), and treatment history and need were evalu- other auto-immune diseases, including asthma, atopic ated. Prevalence of nail involvement in AA was 64.1%. dermatitis, and vitiligo (6). ermato- The specific nail signs reported most frequently were Many patients with AA also have nail involvement, D pitting (29.7%, p = 0.008) and trachyonychia (18.0%).